Roth MKM Initiates Coverage of Natera with Buy Rating

Roth MKM has begun coverage of Natera, Inc. (NTRA) with a Buy rating and established a price target of $475 per share. This move offers a fresh market perspective on the clinical genetic testing company's future outlook.